Bliss GVS Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/05/2025 ,inter alia, to consider and approve a) The Audited Standalone ....

Revenue declinedEBITDA margin expansionResults View source PDF Explain this filing

BLISSGVS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-3.9%Reaction day

₹117.98

prior close

₹118.30

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-2.6%-1.3% vs market

Pharmaceuticals peers, median of 147sector-2.3%-1.6% vs sector

On the reaction day the stock moved 1.3 pts less than Nifty Microcap 250 and 1.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.4

10m

-1.8

15m

-1.7

30m

-1.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-3.9-2.6-1.3-2.3-1.6

Next day

-1.8-1.4-0.4-1.8+0.0

-5.5-2.2-3.3-3.0-2.5

-4.3-2.3-2.0-3.6-0.7

+0.9+2.2-1.3-0.4+1.3

+0.0+3.9-3.8+0.9-0.9

+2.4+6.6-4.2+2.6-0.2

15d

+10.6+9.5+1.1+4.5+6.1

+15.3+11.4+3.9+3.5+11.8

+38.1+13.8+24.3+5.8+32.3

+47.1+9.9+37.2+2.2+44.8

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 147Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Bliss GVS Pharma has informed stock exchanges that its Board of Directors will meet on Monday, May 12, 2025. The Board will consider and approve the audited standalone and consolidated financial results for the quarter and full year ended March 31, 2025, along with the balance sheet, cash flow statement, and audit report. It will also approve the audited financial statements for FY25 and consider recommending a final dividend, if any. The trading window for designated persons has been closed since April 1, 2025 and will reopen 48 hours after the results are announced.

Likely market impact

This is a routine pre-results announcement and signals that Q4 and FY25 earnings, plus the final dividend decision, are due on May 12. Investors should watch for the actual results, dividend declaration, and any modified audit opinion, as these could move the stock.

By the numbersConsolidated · Q4 FY25 vs Q4 FY24

	Q4 FY25	Q4 FY24	Change
Revenue	₹198.0 Cr	₹198.1 Cr	−0.1%
Operating profit	₹11.37 Cr	₹19.65 Cr	−42.1%
Profit after tax	₹16.65 Cr	−₹4.91 Cr	turned positive
EBITDA margin	10.7%	-0.4%	+11.1 pp

From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.